Equity Profile

BCRX

BioCryst Pharmaceuticals, Inc.

Health CareBiotechnology$2.5B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing innovative treatments for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help investors gauge financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential to understand how well the company is expanding its market presence and product adoption.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BCRX Q2-2026 Earnings Preview

Context

Company Snapshot

BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing innovative treatments for rare diseases. With a market cap of $3 billion, it plays a crucial role in the healthcare sector, particularly in addressing unmet medical needs through its specialized drug development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-346.07%

Avg Stock Reaction

+1.71%

Last Quarter Recap

In Q1-2026, BioCryst reported an EPS of -$2.98, significantly missing estimates, which raised concerns about its financial trajectory. The stock fell 2.21% the following day, reflecting investor disappointment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for BioCryst's upcoming earnings are mixed, given the recent poor performance and lack of analyst estimates. Investors are cautious about whether the company can turn around its financial results.

Bull Case

If BioCryst can demonstrate significant progress in its drug pipeline and report better-than-expected EPS, it could lead to a strong recovery in stock price and renewed investor confidence.

Bear Case

Conversely, if the company continues to report losses and fails to provide clarity on revenue growth, it may face further stock declines and increased skepticism from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be crucial in determining whether the company is moving towards profitability or continuing its trend of losses.

What updates can be provided on the drug pipeline?

Insights into the pipeline's progress can significantly influence investor sentiment and expectations for future revenue.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioCryst's pipeline to yield significant breakthroughs, which could lead to unexpected revenue growth.

Supporting Evidence

The options market is pricing a larger move than historical averages, indicating potential for volatility.

Recent earnings history shows that the company has a 63% EPS beat rate, suggesting a higher likelihood of positive surprises.

The lack of analyst estimates may lead to mispricing of the stock's potential.

Key Risk

If the company reports a significantly better EPS than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will either reinforce or challenge investor confidence in BioCryst's future prospects.

Bull Confirmed If

A positive EPS surprise, indicating a move towards profitability, would confirm the bull case.

Bear Confirmed If

Continued losses and lack of clarity on revenue growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±28.46%

Historical Avg

±9.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±28.5% while BCRX has averaged ±9.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

53.1%

Calls (128K)P/C Ratio: 0.23Puts (28K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioCryst beats expectations, history suggests a potential stock increase of around 7.73%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted reactions as investors remain cautious.

Miss

A miss on earnings could lead to a decline of about 8.34%, reflecting ongoing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the progress of key drugs in the pipeline.
2Updates on partnerships or collaborations that could enhance revenue.
3Insights into cost management strategies to improve profitability.
4Any guidance on future earnings expectations.
5Details on market expansion plans and their potential impact on revenue.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing innovative treatments for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help investors gauge financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential to understand how well the company is expanding its market presence and product adoption.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BCRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-346.07%

Avg Stock Reaction

+1.71%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BioCryst can demonstrate significant progress in its drug pipeline and report better-than-expected EPS, it could lead to a strong recovery in stock price and renewed investor confidence.

Bear Case

Conversely, if the company continues to report losses and fails to provide clarity on revenue growth, it may face further stock declines and increased skepticism from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be crucial in determining whether the company is moving towards profitability or continuing its trend of losses.

What updates can be provided on the drug pipeline?

Insights into the pipeline's progress can significantly influence investor sentiment and expectations for future revenue.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioCryst's pipeline to yield significant breakthroughs, which could lead to unexpected revenue growth.

Supporting Evidence

The options market is pricing a larger move than historical averages, indicating potential for volatility.

Recent earnings history shows that the company has a 63% EPS beat rate, suggesting a higher likelihood of positive surprises.

The lack of analyst estimates may lead to mispricing of the stock's potential.

Key Risk

If the company reports a significantly better EPS than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will either reinforce or challenge investor confidence in BioCryst's future prospects.

Bull Confirmed If

A positive EPS surprise, indicating a move towards profitability, would confirm the bull case.

Bear Confirmed If

Continued losses and lack of clarity on revenue growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±28.46%

Historical Avg

±9.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±28.5% while BCRX has averaged ±9.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

53.1%

Calls (128K)P/C Ratio: 0.23Puts (28K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioCryst beats expectations, history suggests a potential stock increase of around 7.73%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted reactions as investors remain cautious.

Miss

A miss on earnings could lead to a decline of about 8.34%, reflecting ongoing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the progress of key drugs in the pipeline.
2Updates on partnerships or collaborations that could enhance revenue.
3Insights into cost management strategies to improve profitability.
4Any guidance on future earnings expectations.
5Details on market expansion plans and their potential impact on revenue.